[1] White AM, Castle IP, Powell PA, et al. Alcohol-related deaths during the COVID-19 pandemic. JAMA, 2022,327(17):1704-1706.
[2] Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med, 2009,360(26):2758-2769.
[3] Singal AK, Kwo P, Kwong A, et al. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology, 2022,75(4):1026-1037.
[4] Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015,372(17):1619-1628.
[5] Szabo G, Mitchell M, McClain CJ, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology, 2022,76(4):1058-1068.
[6] Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: A double-blind randomized controlled trial. Hepatology, 2019,70(3):802-811.
[7] Kimer N, Meldgaard M, Hamberg O, et al. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial. PLoS One, 2022,17(3):e0264278.
[8] Louvet A, Labreuche J, Moreno C, et al. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: A prospective controlled study. Lancet Gastroenterol Hepatol, 2022,7(5):416-425.
[9] Li X, Liu Y, Guo X, et al. Effect of lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury. Eur J Clin Nutr, 2021,75(8):1227-1236.
[10] Mathurin P, Thursz M. Endpoints and patient stratification in clinical trials for alcoholic hepatitis. J Hepatol, 2019,70(2):314-318.
[11] Glasziou PP, Tikkinen K. The RECOVERY trial platform: A milestone in the development and execution of treatment evaluation during an epidemic. J R Soc Med, 2021,114(9):443-446.
[12] Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med, 2021,384(8):693-704.
[13] Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med, 2020,383(21):2030-2040.
[14] Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 2020,396(10259):1345-1352.
[15] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 2021,397(10285):1637-1645.
[16] Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 2022,399(10325):665-676.
[17] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 2022,399(10320):143-151.
[18] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet Respir Med, 2021,9(12):1419-1426.
[19] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, open-label, platform trial. Lancet, 2021,397(10289):2049-2059.
[20] Lucey MR, Thursz MR. We need a new approach to clinical trials in alcohol-associated hepatitis: Is there a lesson in RECOVERY? Hepatology, 2022,76(4):909-910.
[21] Pessoa-Amorim G, Campbell M, Fletcher L, et al. Making trials part of good clinical care: Lessons from the RECOVERY trial. Future Healthc J, 2021,8(2):e243-e250.
[22] Peto L, Horby P, Landray M. Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial. Adv Biol Regul, 2022:100901. |
